Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bushen Qiangdu Sanhan granule for ankylosing spondylitis
ChiCTR2300070592Phase 3Not yet recruiting
- Sponsor
- Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Bushen Qiangdu Sanhan granule with Placebo (2 arms). Primary endpoints: Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) and Traditional Chinese Medicine Syndrome Score Scale. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
Bushen Qiangdu Sanhan granule
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2300070592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070592.